Common MDS drug shows promise in treating AML
Results from a phase II trial carried out by researchers at the Ohio State University Comprehensive Cancer Center in Columbus suggest that a drug used to treat people with myelodysplastic syndrome (MDS) may also be effective in treating some leukemia patients.
BLOOD CANCER SUBTYPE(S) IN QUESTION
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Over time, MDS can evolve into AML.
COHORT
Patients: 53 (ages 60 or over)
Median age: 74
RESEARCH FINDINGS
The trial featured the drug decitabine (Dacogen), a single agent chemotherapeutic drug and DNA methyltransferase inhibitor used against MDS. In the cohort with AML, the drug resulted in a complete response in 47% of patients, with an overall response rate of 64%.
It should be noted that this trial did not have a control group, so it's impossible to say how the drug would measure up against other drugs or regimens.
PUBLICATION & SOURCES
This study was published online in the Proceedings of the National Academy of Sciences. .
Source: MedPageToday
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
